Physician profile
David J Brown
NPI 1225071962
$56,072.73
in general payments reported to CMS, 2019-2025
36 companies · $5,354 in 2025
The $5,354 reported for 2025 was more than what 86% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $7,292 · 2021: $4,132 · 2022: $4,627 · 2023: $5,615 · 2024: $5,526 · 2025: $5,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Education: $319 · Travel and Lodging: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,027.76 |
| Education | $318.97 |
| Travel and Lodging | $147.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $25,796.57 | 2019-2025 | |
| Janssen Biotech, INC. | $5,442.61 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Amgen INC. | $5,350.89 | 2019-2025 | Evenity, Otezla, Enbrel |
| Abbvie INC. | $3,389.05 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $2,200.97 | 2019-2025 | Cimzia, Bimzelx |
| Lilly USA, LLC | $1,795.92 | 2019-2025 | Taltz, Omvoh, Mounjaro |
| Mallinckrodt Hospital Products INC. | $1,662.26 | 2020-2025 | Acthar |
| Genentech USA, INC. | $1,381.13 | 2019-2025 | Actemra, Rituxan |
| Pfizer INC. | $1,240.56 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,172.91 | 2021-2025 | Saphnelo |
| Janssen Scientific Affairs, LLC | $969.75 | 2019-2022 | |
| Horizon Therapeutics Plc | $897.31 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $727.14 | 2020-2025 | Benlysta |
| Sobi, INC | $659.55 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $634.08 | 2020-2025 | Ofev, Cyltezo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $472.80 | 2019-2025 | Orencia |
| Fresenius Kabi USA, LLC | $376.57 | 2023-2025 | Idacio |
| Genzyme Corporation | $257.13 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $249.41 | 2019 | |
| Fidia Pharma USA INC. | $170.04 | 2019-2025 | Hymovis, Triluron |
| Genentech, INC. | $159.80 | 2019 | |
| Ani Pharmaceuticals, INC. | $153.63 | 2022-2025 | Purified Cortrophin Gel |
| Bioventus LLC | $136.50 | 2019-2025 | Gelsyn-3 |
| Takeda Pharmaceuticals U.S.A., INC. | $120.68 | 2020-2024 | Entyvio |
| Organon LLC | $112.91 | 2021-2025 | Hadlima, Renflexis |
| Antares Pharma, INC. | $95.88 | 2020-2021 | |
| Sandoz INC. | $92.41 | 2024-2025 | Hyrimoz, Jubbonti |
| Radius Health, INC. | $77.41 | 2019-2023 | Tymlos |
| Actelion Pharmaceuticals US, INC. | $50.96 | 2025 | Opsumit |
| Pacira Therapeutics, INC. | $50.40 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $43.98 | 2020-2022 | |
| Ultragenyx Pharmaceutical INC. | $42.99 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $26.81 | 2022 | |
| Aurinia Pharma U.S., INC. | $23.29 | 2021 | |
| Novo Nordisk INC | $22.13 | 2020 | |
| Baudax Bio INC. | $16.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.